Toll Free: 1-888-928-9744

Celator Pharmaceuticals, Inc. - Product Pipeline Review - 2014

Published: May, 2014 | Pages: 33 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Celator Pharmaceuticals, Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Celator Pharmaceuticals, Inc. - Product Pipeline Review - 2014', provides an overview of the Celator Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Celator Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Celator Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Celator Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Celator Pharmaceuticals, Inc.'s pipeline products

Reasons to buy

- Evaluate Celator Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Celator Pharmaceuticals, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Celator Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Celator Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Celator Pharmaceuticals, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Celator Pharmaceuticals, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Celator Pharmaceuticals, Inc. Snapshot 4
Celator Pharmaceuticals, Inc. Overview 4
Key Information 4
Key Facts 4
Celator Pharmaceuticals, Inc. - Research and Development Overview 5
Key Therapeutic Areas 5
Celator Pharmaceuticals, Inc. - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Pipeline Products - Combination Treatment Modalities 9
Celator Pharmaceuticals, Inc. - Pipeline Products Glance 10
Celator Pharmaceuticals, Inc. - Late Stage Pipeline Products 10
Phase III Products/Combination Treatment Modalities 10
Celator Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 11
Phase II Products/Combination Treatment Modalities 11
Phase I Products/Combination Treatment Modalities 12
Celator Pharmaceuticals, Inc. - Early Stage Pipeline Products 13
Preclinical Products/Combination Treatment Modalities 13
Celator Pharmaceuticals, Inc. - Drug Profiles 14
(cytarabine + daunorubicin) 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
(irinotecan hydrochloride + floxuridine) 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
(irinotecan hydrochloride + cisplatin) 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
CPX-8 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Celator Pharmaceuticals, Inc. - Pipeline Analysis 22
Celator Pharmaceuticals, Inc. - Pipeline Products by Target 22
Celator Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 23
Celator Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 24
Celator Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 25
Celator Pharmaceuticals, Inc. - Recent Pipeline Updates 26
Celator Pharmaceuticals, Inc. - Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Appendix 32
Methodology 32
Coverage 32
Secondary Research 32
Primary Research 32
Expert Panel Validation 32
Contact Us 33
Disclaimer 33
List of Tables
Celator Pharmaceuticals, Inc., Key Information 4
Celator Pharmaceuticals, Inc., Key Facts 4
Celator Pharmaceuticals, Inc. - Pipeline by Indication, 2014 6
Celator Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2014 7
Celator Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2014 8
Celator Pharmaceuticals, Inc. - Combination Treatment Modalities in Pipeline, 2014 9
Celator Pharmaceuticals, Inc. - Phase III, 2014 10
Celator Pharmaceuticals, Inc. - Phase II, 2014 11
Celator Pharmaceuticals, Inc. - Phase I, 2014 12
Celator Pharmaceuticals, Inc. - Preclinical, 2014 13
Celator Pharmaceuticals, Inc. - Pipeline by Target, 2014 22
Celator Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2014 23
Celator Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2014 24
Celator Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2014 25
Celator Pharmaceuticals, Inc. - Recent Pipeline Updates, 2014 26
Celator Pharmaceuticals, Inc., Subsidiaries 31 



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify